The purpose of this study was to assess characteristics, treatment outcomes and complications in patients with locally advanced or recurrent gynecological malignancies treated with interstitial brachytherapy using MUPIT. Materials and Methods: We performed a retrospective review of all patients with gynecological malignancies treated with MUPIT in a single institution between January 2005 and May 2014. Cases without data or follow up were excluded. Information recorded were demographic and clinic characteristics, previous use of RT (external or BT), dose rate of interstitial BT, local control rate, late toxicity and mortality rate. Categorical variables are presented as frequencies and proportions, and continuous variables as the mean, median, and range. Local recurrence-free survival (LRFS) and overall survival (OS) after MUPIT treatment were estimated using the Kaplan-Meier method. Results: Forty six patients were identified. The median age was 64 years (range, 28 -85). Cervical and endometrial cancers were the most common primary site, with 20 and 16 cases respectively. The indications of interstitial BT were treatment of local recurrence (31), primary tumor (14) and metastases (1). Forty patients received external RT or BT before interstitial BT. High dose rate BT was used in 37 cases. Median LRFS was 76.2 months (CI 95% 61.6 -90.7) and the median survival time was 82 months (CI 95% 67.5 -96.5). There have been no cases of Grade IV late toxicity. Proctitis and pelvic pain were the most common grade III complications (4 patients). Conclusions: Interstitial BT using MUPIT applicator is an effective treatment which obtains high rates of local control despite the bad prognosis of pelvic recurrencies. Secondary effects are few, and manageable. magnitude of response is dependent on time points of evaluation. The predictive power of these changes on long term treatment outcome is object of ongoing prospective study.
Purpose/Objective: Bone marrow sparing using intensitymodulated radiotherapy (IMRT) could reduce haematological toxicity from radical chemoradiation for cervical carcinoma. One challenge is to determine the location of functioning bone marrow rather than attempt to spare the whole bony pelvis. On FDG-PET the areas of higher activity correlate with SUV values, and the scans used to stage disease could potentially be used to also identify functioning bone marrow. The aims of this study were to identify functioning pelvic bone marrow using FDG-PET, to analyse the pattern of distribution between patients and to develop guidelines for defining bone marrow as an organ at risk which can be applied to radiotherapy CT scans for all patients. Materials and Methods: The FDG-PET scans from 10 patients treated for cervical cancer were assessed. Structure sets consisting 6 absolute SUV thresholds (0.5,1.0, 1.5, 2.0, 2.5 and 3.0) were created. The distribution of SUV activity within each pelvic subregion and the whole bony pelvis was analysed. The maximum SUV value within the bony pelvis (SUVmax) was defined as the highest level with a volume > 1cc. Volumetric data for SUVMax, SUV >75%Max (SUV75) and SUV>50%Max (SUV50) were compared, measuring the contribution to each region and to the total activity. Results: The absolute SUV values within the pelvis varied between patients whereas relative values were more comparable. A reproducible pattern of distribution was evident in all patients using SUV75. The highest activity is seen within the lumbar spine, sacrum, posterior iliac alae and pubic bone contributing 86.67% total activity. For SUV75, the SUV range was 1.0 -2.5 with a mean volume of 98.9cc SD 50. 3), which is 6.9% (range 1.7 -12.9, SD 3.2) of the mean total pelvic volume. Conclusions: There is a reproducible pattern of functional bone marrow on FDG-PET within the pelvis. Guidelines for contouring a standard avoidance structure on the planning CT scan have been generated which encompass the areas of highest activity. Bone marrow avoidance should be assessed further in dosimetric and clinical studies.
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Materials and Methods:
Seven patients underwent 18 F-FMISO-PET/CT and MP-MRI at baseline; 2 and 5 weeks(w) after treatment start and 3 months after treatment end. Data were registered, fused and analyzed using Mirada RTx software (Mirada Medical Ltd, Oxford,UK). Gross tumour volume (GTV) was contoured by an experienced radiation oncologist on PET/MRI data sets. The volume of GTV was analysed for size, EH-kinetics, diffusivity and 18 F-FMISO-avidity using SUVmax and SUV-normalized to gluteal muscle uptake. At follow up, cervix was contoured, since all patients showed clinically complete remission. Results: Median GTV volume was 43.9cc at baseline, 22.4cc after 2w (20-25Gy) and 7.7cc after 5w (40-45Gy). Mean ADC values were 1.02x10 -3 mm 2 /sec increasing to 1.18x10 -3 mm 2 /sec after 2w and to 1.27x10 -3 mm 2 /sec after 5w and were 1.37x10 -3 mm 2 /sec at 3 months. All GTVs showed mean initial-enhancement (IE) followed by a plateau with an increasing IE at 2w and 5w and wash-out at 5w. At follow-up, the mean IE was 120% followed by a persistent enhancement. The mean 18 F-FMISO SUV-norm was 3.1 at baseline and decreased to 2.3 at 2w and 2.0 at 5w and follow-up. Conclusions: There are morphological and functional changes in tumor diffusion, perfusion and hypoxia during treatment which can be non-invasively monitored with MP-MRI/PET. The
